CA2896962A1 - Composes liant l'albumine serique humaine et proteines de fusion correspondantes - Google Patents

Composes liant l'albumine serique humaine et proteines de fusion correspondantes Download PDF

Info

Publication number
CA2896962A1
CA2896962A1 CA2896962A CA2896962A CA2896962A1 CA 2896962 A1 CA2896962 A1 CA 2896962A1 CA 2896962 A CA2896962 A CA 2896962A CA 2896962 A CA2896962 A CA 2896962A CA 2896962 A1 CA2896962 A1 CA 2896962A1
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
seq
acid sequence
serum albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2896962A
Other languages
English (en)
Inventor
Fabian Buller
Ulrich Wullner
Irene Zbinden
Isabella Attinger-Toller
Ulrike Von Der Bey
Susann Konig-Friedrich
Julian Bertschinger
Dragan Grabulovski
Patricia Henne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Covagen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen AG filed Critical Covagen AG
Publication of CA2896962A1 publication Critical patent/CA2896962A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2896962A 2013-01-03 2013-12-18 Composes liant l'albumine serique humaine et proteines de fusion correspondantes Abandoned CA2896962A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13150171.0A EP2752426A1 (fr) 2013-01-03 2013-01-03 Composés de liaison d'albumine de sérum humain et leurs protéines de fusion
EP13150171.0 2013-01-03
PCT/EP2013/077227 WO2014106583A1 (fr) 2013-01-03 2013-12-18 Composés liant l'albumine sérique humaine et protéines de fusion correspondantes

Publications (1)

Publication Number Publication Date
CA2896962A1 true CA2896962A1 (fr) 2014-07-10

Family

ID=47458817

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896962A Abandoned CA2896962A1 (fr) 2013-01-03 2013-12-18 Composes liant l'albumine serique humaine et proteines de fusion correspondantes

Country Status (7)

Country Link
US (2) US9790475B2 (fr)
EP (2) EP2752426A1 (fr)
JP (1) JP2016508143A (fr)
AU (1) AU2013372004B2 (fr)
CA (1) CA2896962A1 (fr)
HK (1) HK1215441A1 (fr)
WO (1) WO2014106583A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925862A1 (fr) 2013-10-01 2015-04-09 Glaxosmithkline Intellectual Property Development Limited Composes pour chromatographe d'affinite, destines a prolonger la demi-vie d'un agent therapeutique
WO2018151868A2 (fr) 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Protéines de fusion à domaine de liaison à l'albumine
CN107353346A (zh) * 2017-08-09 2017-11-17 芜湖英特菲尔生物制品产业研究院有限公司 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
CN116284375A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
WO2002076489A1 (fr) 2001-03-09 2002-10-03 Dyax Corp. Groupes de liaison d'albumine serique
CA2505325C (fr) 2002-11-08 2014-02-25 Ablynx N.V. Anticorps a domaine unique stabilises
EP1892248A1 (fr) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Protéines liantes spécifiques et de haute affinité comprenant des domaines SH3 de FYN kinase modifiés
EP2524927A1 (fr) * 2011-05-20 2012-11-21 Covagen AG Nouveaux composés de liaison de chymase et utilisations médicales associées
CA2865597A1 (fr) * 2012-03-16 2013-09-19 Covagen Ag Nouvelles molecules de liaison a activite antineoplasique

Also Published As

Publication number Publication date
AU2013372004A1 (en) 2015-07-16
US9790475B2 (en) 2017-10-17
WO2014106583A1 (fr) 2014-07-10
US10364419B2 (en) 2019-07-30
EP2752426A1 (fr) 2014-07-09
EP2941439A1 (fr) 2015-11-11
AU2013372004B2 (en) 2017-05-25
US20190169581A1 (en) 2019-06-06
EP2941439B1 (fr) 2018-01-31
JP2016508143A (ja) 2016-03-17
US20160076011A1 (en) 2016-03-17
HK1215441A1 (zh) 2016-08-26

Similar Documents

Publication Publication Date Title
US10364419B2 (en) Human serum albumin binding compounds and fusion proteins thereof
US20210198380A1 (en) Anti-cancer fusion polypeptide
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
EP3896083B1 (fr) Protéines de fusion fc comprenant de nouveaux lieurs et arrangements
RU2628699C2 (ru) Trail r2-специфические мультимерные скаффолды
JP2015528003A (ja) 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体
KR20160002882A (ko) 항종양 활성을 갖는 신규한 이중특이적 결합 분자
CA2790329A1 (fr) Proteines de domaine d'echafaudage a base de fibronectine qui se lient a il-23
US20210395318A1 (en) Multispecific proteins
EA031683B1 (ru) Полипептид, ингибирующий активность гликозилированного il-17a, и его применение
JP2020515262A (ja) 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
JP6840907B2 (ja) ＦＧＦＲ３結合分子ｌｋｏｋｏｋ
CN117242094A (zh) 蛋白酶可切割的前药

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20191218